L. delbrueckii

NutraPedia - Evidence-Based Supplement Research

Back to Table of Contents
Health Goals: digestion immunity inflammation

Research Overview

Across the provided abstracts, Lactobacillus delbrueckii is most frequently studied in the context of (i) gastrointestinal infection/inflammation and barrier function (primarily preclinical models), and (ii) metabolic and pregnancy-related outcomes when delivered as part of multi-strain probiotic formulations in humans. A prominent mechanistic line of work examines how prebiotics such as galactooligosaccharides (GOS) enrich specific lactobacilli in vivo and how enriched strains differ in function; in this setting, L. delbrueckii has been investigated for immunomodulatory effects (e.g., macrophage polarization) and impacts on microbial metabolites (e.g., propionate). Additional, more applied research threads appear in food fermentation and dairy/soy processing (e.g., starter culture performance, sensory/digestibility changes), though the excerpts provided are incomplete and do not allow strong conclusions about clinical relevance from those studies.

The strongest evidence in these abstracts supports two points. First, in animal models of enteric infection, a specific strain (L. delbrueckii ATCC® BAA-365™) showed protective effects against Salmonella-associated intestinal inflammation and barrier dysfunction, with proposed mechanisms including increased propionate and suppression of JAK2–STAT3 signaling and M1 macrophage polarization; importantly, this effect was strain-specific relative to other GOS-enriched lactobacilli. Second, in humans, evidence for L. delbrueckii is currently most direct when it is included in multi-strain probiotic capsules: in a randomized, double-blind, placebo-controlled trial in gestational diabetes mellitus, a formulation containing L. delbrueckii subsp. bulgaricus (LBY-27) alongside other strains improved several inflammatory and oxidative stress biomarkers versus placebo. By contrast, broader meta-analytic evidence indicates modest improvements in metabolic risk factors from probiotics overall, but those benefits were “mostly observed with bifidobacteria,” implying that the specific contribution of L. delbrueckii to metabolic endpoints remains uncertain in the current human literature summarized here.

Key gaps and needs for further research include: (i) more strain-resolved human trials testing L. delbrueckii alone (or in factorial designs) to attribute effects independently from co-administered species; (ii) replication and translation of mechanistic findings (e.g., propionate modulation, JAK2–STAT3 effects, macrophage polarization) from animal models to humans, including dose–response and durability after cessation; and (iii) clearer linkage between food/fermentation applications of L. delbrueckii (e.g., in yogurt/soy fermentation) and measurable host health outcomes. Additional work is also needed on colonization dynamics and host–microbe interactions (including metabolomics and immune profiling) to determine which strains, contexts (prebiotic co-administration), and populations are most likely to benefit.

1. What conditions has L. delbrueckii been studied for?

  • Gestational diabetes mellitus (GDM) (pregnant women): tested as part of a multi-strain probiotic capsule that included L. delbrueckii bulgaricus (LBY-27) for effects on inflammation and oxidative stress biomarkers.

  • Immune aging / immunosenescence in older adults: L. delbrueckii subsp. bulgaricus 8481 studied for effects on immune cell profiles, cytokines, and antimicrobial peptides over 6 months.

  • Enteric infection and intestinal inflammation/barrier dysfunction (animal model): L. delbrueckii (ATCC® BAA 365™) studied in Salmonella-infected mice, in the context of GOS (galactooligosaccharide) supplementation that enriched certain lactobacilli.

  • Metabolic risk factors related to obesity, type 2 diabetes, and fatty liver disease: probiotics broadly were meta-analyzed across RCTs; the abstract notes benefits were “mostly observed with bifidobacteria,” and does not isolate effects of L. delbrueckii specifically.

  • Bee gut infection (Nosema ceranae) (honey bees): L. delbrueckii included as one component of a multi-strain commercial probiotic tested for spore load and survivorship (effects cannot be attributed to L. delbrueckii alone).

  • Probiotic screening/characterization studies (in vitro): multiple abstracts describe evaluating Lactobacillus strains (including L. delbrueckii subspecies) for acid/bile tolerance, adhesion, antibiotic sensitivity, antioxidant activity, aggregation, etc. These are not clinical conditions but relate to probiotic potential.

2. Does it work in treating those conditions? Summarize the evidence.

  • GDM (human RCT; multi-strain, not L. delbrueckii-only): In a double-blind placebo-controlled trial (64 women, 8 weeks), the probiotic capsule containing L. delbrueckii bulgaricus (with L. acidophilus, Bifidobacterium, and S. thermophilus) significantly improved several biomarkers versus placebo: hs-CRP and TNF-α improved; malondialdehyde, glutathione reductase, and erythrocyte glutathione peroxidase improved. IL-6 decreased in both groups but was not significantly different between groups. Because it was a combination product, the specific contribution of L. delbrueckii is uncertain.

  • Immune aging in elderly (human RCT; L. delbrueckii-specific): In a multi-center double-blind placebo-controlled study (61 elderly; 6 months; at least 3×107 CFU per capsule, three capsules/day), L. delbrueckii subsp. bulgaricus 8481 was associated with increased NK cell percentage, improved immune risk profile parameters, shifts toward less-differentiated T-cell subsets, decreased IL-8, and increased human β-defensin-2 (hBD-2). Effects disappeared within 6 months after stopping supplementation. This supports an immunomodulatory effect during active use, but it does not directly demonstrate reduced infections or clinical endpoints.

  • Salmonella intestinal inflammation/barrier dysfunction (animal; L. delbrueckii-specific): In Salmonella-infected mice, L. delbrueckii (ATCC® BAA 365™) (identified as GOS-enriched) improved outcomes by enhancing intestinal propionate production and reducing inflammation and barrier dysfunction, mechanistically linked to suppression of JAK2-STAT3 signaling and M1 macrophage polarization. This is promising mechanistic/efficacy evidence in animals, but not proof of benefit in humans.

  • Obesity/T2D/NAFLD metabolic outcomes (human meta-analysis; probiotics broadly): A systematic review/meta-analysis of 105 RCTs (6826 subjects) found probiotics produced small but consistent improvements in multiple metabolic risk factors (e.g., in type 2 diabetes: fasting glucose −0.66 mmol/L; HbA1c −0.28 percentage points; insulin −1.66 mU/L; HOMA-IR −1.05). However, the abstract states improvements were “mostly observed with bifidobacteria,” and does not provide L. delbrueckii-specific efficacy. Therefore, this supports probiotics as a category, but is weak evidence for L. delbrueckii specifically.

  • Nosema infection in bees (non-human; multi-strain): Multi-strain products that included L. delbrueckii were tested; some probiotic regimens reduced spore loads and improved survival, but the most clearly “promising” result in the abstract was a single-strain Enterococcus faecium product. The role of L. delbrueckii cannot be isolated.

3. What health benefits does it have?

  • Immune modulation in older adults (human evidence): Supplementation with L. delbrueckii subsp. bulgaricus 8481 increased NK cell percentage, improved immune risk profile parameters, shifted T-cell subsets toward less differentiated phenotypes, decreased IL-8 (a pro-inflammatory cytokine), and increased hBD-2 (an antimicrobial peptide). Benefits were present during supplementation and waned after discontinuation.

  • Improved inflammation/oxidative stress biomarkers in GDM (human evidence; multi-strain): In women with newly diagnosed GDM, a probiotic containing L. delbrueckii bulgaricus improved hs-CRP and TNF-α and improved oxidative stress markers (malondialdehyde, glutathione reductase, erythrocyte glutathione peroxidase) compared with placebo; attribution to L. delbrueckii alone is not possible.

  • Gut barrier protection and anti-inflammatory effects in infection (animal evidence): In Salmonella-infected mice, L. delbrueckii (ATCC® BAA 365™) reduced intestinal inflammation and barrier dysfunction, associated with increased propionate and downregulation of JAK2-STAT3 signaling and M1 macrophage polarization.

  • Potential probiotic-functional traits (in vitro evidence): Screening studies described strain-dependent properties relevant to probiotic function (e.g., resistance to acid/bile/pancreatic enzymes, adhesion, antioxidant activity, aggregation, antibacterial activity, and antibiotic sensitivity). These findings support plausibility but do not guarantee clinical benefit.

4. Does it have any downsides or side effects?

  • Human trials in the provided abstracts did not report major adverse events for L. delbrueckii interventions (elderly immune study; GDM multi-strain study), but the abstracts also do not provide detailed safety reporting, so absence of evidence is not evidence of absence.

  • Effects may be transient and require continued intake: In the elderly study, immunologic changes “disappeared within 6 months of stopping the probiotic intake,” suggesting benefits may not persist after discontinuation.

  • Strain-dependent antibiotic susceptibility/resistance patterns: In vitro characterization work notes LAB strains were “sensitive to a wide range of antibiotics” with differences between strains, and emphasizes strain-dependent properties. This is not a direct “side effect,” but it matters for safety assessment and for use alongside antibiotics.

  • Not all Lactobacillus strains are beneficial in all contexts: The Salmonella mouse study showed different Lactobacillus species had different protective effects (e.g., L. reuteri failed to protect), underscoring that benefits are not guaranteed across strains/species; this is a limitation rather than a known harm.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

The provided abstracts do not report pharmacogenomic findings (e.g., host genetic variants that predict response or adverse effects) for L. delbrueckii. The evidence here supports strain-specific biological effects (e.g., immune modulation; effects on JAK2-STAT3 signaling in mice), but it does not link those effects to human genetic variation. Any claims about genotype-specific benefit or harm would be speculative based on these abstracts alone.

References

  1. Impact of bacterial probiotics on obesity, diabetes and non-alcoholic fatty liver disease related variables: a systematic review and meta-analysis of randomised controlled trials.
    Hana Koutnikova, Bernd Genser, Milena Monteiro-Sepulveda, Jean-Michel Faurie, Salwa Rizkalla, Jürgen Schrezenmeir, Karine Clément (2019) - BMJ open
  2. Strain specificity of lactobacilli with promoted colonization by galactooligosaccharides administration in protecting intestinal barriers during Salmonella infection.
    Yujun Wu, Xiangyu Zhang, Xiaoyi Liu, Yi Li, Dandan Han, Yu Pi, Melanie A Whitmore, Xingmiao Lu, Guolong Zhang, Jinkai Zheng, Junjun Wang (2024) - Journal of advanced research
  3. Non-beany flavor soymilk fermented by lactic acid bacteria: Characterization, stability, antioxidant capacity and
    Chunyan Huo, Xiaoyu Yang, Liang Li (2023) - Food chemistry: X
  4. Effects of Prebiotics and Probiotics on Honey Bees (Apis mellifera) Infected with the Microsporidian ParasiteNosema ceranae
    Daniel Borges, Ernesto Guzman-Novoa, Paul H Goodwin (2021)
  5. Probiotic Properties and Neuroprotective Effects of
    Min-Jeong Cheon, Sung-Min Lim, Na-Kyoung Lee, Hyun-Dong Paik (2020) - International journal of molecular sciences
  6. Specific properties of probiotic strains: relevance and benefits for the host.
    Rostyslav V Bubnov, Lidiia P Babenko, Liudmyla M Lazarenko, Victoria V Mokrozub, Mykola Ya Spivak (2018) - The EPMA journal
  7. Effect of probiotic supplements in women with gestational diabetes mellitus on inflammation and oxidative stress biomarkers: a randomized clinical trial.
    Majid Hajifaraji, Fatemeh Jahanjou, Fatemeh Abbasalizadeh, Nasser Aghamohammadzadeh, Mehran Mesgari Abbasi, Neda Dolatkhah (2018) - Asia Pacific journal of clinical nutrition
  8. Physicochemical, Rheological, and Sensory Characteristics of Yogurt Fermented by Lactic Acid Bacteria with Probiotic Potential and Bioprotective Properties.
    Ramize Hoxha, Yana Evstatieva, Dilyana Nikolova (2023) - Foods (Basel, Switzerland)
  9. The Role of Bifidobacteria in Predictive and Preventive Medicine: A Focus on Eczema and Hypercholesterolemia.
    Luisa Marras, Michele Caputo, Sonia Bisicchia, Matteo Soato, Giacomo Bertolino, Susanna Vaccaro, Rosanna Inturri (2021) - Microorganisms
  10. Understanding the bacterial communities of hard cheese with blowing defect.
    Daniela Bassi, Edoardo Puglisi, Pier Sandro Cocconcelli (2015) - Food microbiology
  11. Local Probiotic
    Ting Li, Zhaohui Liu, Xu Zhang, Xi Chen, Suxia Wang (2019) - Frontiers in microbiology
  12. Genomic Characterization of
    Paulraj Kanmani, Leonardo Albarracin, Hisakazu Kobayashi, Elvira Maria Hebert, Lucila Saavedra, Ryoya Komatsu, Brian Gatica, Ayako Miyazaki, Wakako Ikeda-Ohtsubo, Yoshihito Suda, Hisashi Aso, Shintaro Egusa, Takashi Mishima, Alexis Salas-Burgos, Hideki Takahashi, Julio Villena, Haruki Kitazawa (2018) - Frontiers in immunology
  13. Oral supplementation with Lactobacillus delbrueckii subsp. bulgaricus 8481 enhances systemic immunity in elderly subjects.
    Marco Antonio Moro-García, Rebeca Alonso-Arias, Maria Baltadjieva, Carlos Fernández Benítez, Manuel Amadeo Fernández Barrial, Enrique Díaz Ruisánchez, Ricardo Alonso Santos, Magdalena Alvarez Sánchez, Juan Saavedra Miján, Carlos López-Larrea (2013) - Age (Dordrecht, Netherlands)
  14. The effect of lactobacillus cell size on its probiotic characteristics.
    Shadi Rajab, Fatemeh Tabandeh, Mahvash Khodabandeh Shahraky, Samira Alahyaribeik (2020) - Anaerobe
  15. Lactobacillus delbrueckii subsp. lactis CKDB001 Ameliorates Metabolic Complications in High-Fat Diet-Induced Obese Mice.
    Hyunsoo Jang, Hyunchae Joung, Jaeryang Chu, Minseo Cho, Yeon-Woo Kim, Kyung Hwan Kim, Chang Hun Shin, Jisu Lee, Jung-Heun Ha (2024) - Nutrients
  16. Lactobacillus delbrueckii CIDCA 133 Ameliorates Chemotherapy-Induced Mucositis by Modulating Epithelial Barrier and TLR2/4/Myd88/NF-κB Signaling Pathway.
    Fernanda Alvarenga Lima Barroso, Luís Cláudio Lima de Jesus, Tales Fernando da Silva, Viviane Lima Batista, Juliana Laguna, Nina Dias Coelho-Rocha, Kátia Duarte Vital, Simone Odília Antunes Fernandes, Valbert Nascimento Cardoso, Enio Ferreira, Flaviano Santos Martins, Mariana Martins Drumond, Pamela Mancha-Agresti, Alexander Birbrair, Debmalya Barh, Vasco Azevedo (2022) - Frontiers in microbiology
  17. Amelioration of regulatory T cells by Lactobacillus delbrueckii and Lactobacillus rhamnosus in pristane-induced lupus mice model.
    Sahar Khorasani, Mahmoud Mahmoudi, Mahmoud Reza Kalantari, Fahimeh Lavi Arab, Seyed-Alireza Esmaeili, Fatemeh Mardani, Nafiseh Tabasi, Maryam Rastin (2019) - Journal of cellular physiology
  18. Anti-inflammatory properties of dairy lactobacilli.
    Clarissa Santos Rocha, Omar Lakhdari, Hervé M Blottière, Sébastien Blugeon, Harry Sokol, Luis G Bermúdez-Humarán, Vasco Azevedo, Anderson Miyoshi, Joël Doré, Philippe Langella, Emmanuelle Maguin, Maarten van de Guchte (2012) - Inflammatory bowel diseases
  19. The effect of glutathione biosynthesis of Streptococcus thermophilus ST-1 on cocultured Lactobacillus delbrueckii ssp. bulgaricus ATCC11842.
    Z P Xue, X Cu, K Xu, J H Peng, H R Liu, R T Zhao, Z Wang, T Wang, Z S Xu (2023) - Journal of dairy science
  20. Safety Evaluation of Lactobacillus delbrueckii subsp. lactis CIDCA 133: a Health-Promoting Bacteria.
    Luís Cláudio Lima de Jesus, Thiago de Jesus Sousa, Nina Dias Coelho-Rocha, Rodrigo Profeta, Fernanda Alvarenga Lima Barroso, Mariana Martins Drumond, Pamela Mancha-Agresti, Ênio Ferreira, Bertram Brenig, Flávia Figueira Aburjaile, Vasco Azevedo (2022) - Probiotics and antimicrobial proteins


Want personalized supplement recommendations based on your genetics?
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!